NASDAQ:NDRA
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. reported net income of −$7.0M in fiscal 2025. Free cash flow was −$5.2M, and the diluted share count rose 289.4%.Summary generated from ENDRA Life Sciences Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−291.6%
Debt / equityn/a
Free cash flow−$5.2M
FCF marginn/a
Share count change+289.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −11 | −13 | −11 | −11 | −6 |
| Net income | −11 | −13 | −10 | −12 | −7 |
| Free cash flow | −11 | −13 | −10 | −7 | −5 |
Recent filings
- 8-KEntry into a material agreement
Oct 1, 2026 - 8-KResults of operations and financial condition
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KOther events
Jul 9, 2026 - 8-KEntry into a material agreement
Jun 26, 2026 - 8-KRegulation FD disclosure
Jun 25, 2026 - 8-KEntry into a material agreement
May 28, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026